Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients

Strahlentherapie und Onkologie, Journal Year: 2024, Volume and Issue: 200(9), P. 774 - 784

Published: March 28, 2024

Abstract Purpose Sarcopenia may complicate treatment in cancer patients. Herein, we assessed whether sarcopenia measurements derived from radiation planning computed tomography (CT) were associated with complications and tumor progression during radiochemotherapy for glioblastoma. Methods Consecutive patients undergoing radiotherapy glioblastoma between 2010 2021 analyzed. Retrocervical muscle cross-sectional area (CSA) was measured via threshold-based semi-automated CT analysis. Patients the lowest sex-specific quartile of defined as sarcopenic. We abstracted characteristics medical records performed uni- multivariable time-to-event analyses. Results included 363 our cohort (41.6% female, median age 63 years, time to 7.7 months). Sarcopenic less likely receive chemotherapy ( p < 0.001) more be treated hypofractionated = 0.005). Despite abbreviated treatment, they often discontinued 0.023) frequently prescribed corticosteroids 0.014). After transferred inpatient palliative care 0.035). Finally, progression-free survival substantially shorter sarcopenic univariable (median 5.1 vs. 8.4 months, modeling (hazard ratio 0.61 [confidence interval 0.46–0.81], 0.001). Conclusion is a strong risk factor discontinuation reduced propose that should intensified supportive follow-up well expedited access care.

Language: Английский

---

Sarcopenia in glioblastoma: the imaging we need and what it tells us

Strahlentherapie und Onkologie, Journal Year: 2024, Volume and Issue: 200(11), P. 992 - 993

Published: Aug. 2, 2024

We thank Abdusalam and Kara for their insightful discussion [1] of our findings [2] appreciate the opportunity to offer thoughts.Abdusalam discuss determination sarcopenia based on planning computed tomography (CT).In doing so, we follow in a tradition high-ranking investigations that have relied upon imaging determine presence (including publications Lancet Oncology, Radiology, JAMA) [2-9].In last 4 years alone, close 40 used term "CT-defined sarcopenia" according search PubMed, including Journal Cachexia, Sarcopenia, Muscle, one most relevant journals field [10].Hence, study's imaging-based definition is well line with large body literature.We are aware an definition, while commonly used, not universally applied: An increasing number studies use definitions rely combination physical function [11,12] or alone [13,14].The need consensus remains pressing, but unmet at this time [15].There similar heterogeneity when it comes type muscle mass assessment, though even some ultrasound-based [16,17] as papers [7,11,12] refer (CT) magnetic resonance (MRI) gold standard.The undeniable advantage study setup available cranial CT scans routinely acquired radiation every glioblastoma patient.Hence, assessment can be performed without additional examinations patients.We observed strong

Language: Английский

---

Efficacy and Low Toxicity of Normo-Fractionated Re-Irradiation with Combined Chemotherapy for Recurrent Glioblastoma—An Analysis of Treatment Response and Failure

Cancers, Journal Year: 2024, Volume and Issue: 16(21), P. 3652 - 3652

Published: Oct. 29, 2024

Glioblastoma is the most common malignant brain tumor in adults. Even after maximal safe resection and adjuvant chemoradiotherapy, patients normally relapse a few years or even months. Standard treatment for recurrent glioblastoma not yet defined, with re-resection, re-irradiation, systemic therapy playing key roles. Usually, re-irradiation combined concurrent chemotherapy, harnessing radiosensitizing effects of alkylating agents.

Language: Английский

---

Body mass index as a prognostic indicator of overall survival in glioblastoma: A systematic review and meta analysis

Journal of Clinical Neuroscience, Journal Year: 2024, Volume and Issue: 133, P. 111019 - 111019

Published: Dec. 30, 2024

Language: Английский

---